Important Information for Regeneron Pharmaceuticals Investors: Rosen Law Firm Announces Class Action Lawsuit and Lead Plaintiff Deadline
On February 23, 2025, Rosen Law Firm, a global investor rights law firm, issued a press release reminding purchasers of securities of Regeneron Pharmaceuticals, Inc. (Regeneron) (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline in a securities class action lawsuit.
Background on the Class Action Lawsuit
The lawsuit alleges that Regeneron and certain of its top executives made false and/or misleading statements and/or failed to disclose material information during the Class Period regarding the development and regulatory approval of its drug, Evkeeza. Specifically, the complaint alleges that the defendants failed to disclose that:
- The safety data for Evkeeza was insufficient to support its approval;
- The drug’s clinical trials were not adequately designed or monitored;
- Regeneron had received negative feedback from the U.S. Food and Drug Administration (FDA) regarding the drug’s safety;
- Regeneron had downplayed the risks associated with Evkeeza;
Effect on Individual Investors
If you purchased Regeneron securities during the Class Period and suffered a loss, you may be eligible to act as a lead plaintiff in the class action. As a lead plaintiff, you may be able to direct the litigation and participate in key decision-making. You do not need to seek approval from the court or pay any upfront costs to be a lead plaintiff.
Effect on the World
The outcome of this class action lawsuit could have significant implications for the biotech industry and the regulatory approval process for new drugs. If the allegations are proven, it could lead to increased scrutiny of drug development and regulatory approval processes, potentially delaying the availability of new treatments to patients. Additionally, it could result in increased liability for pharmaceutical companies and their executives, potentially discouraging investment in the industry.
Conclusion
If you purchased Regeneron securities during the Class Period and believe you may have lost money as a result, you may be eligible to participate in the class action lawsuit. The lead plaintiff deadline is March 10, 2025. For more information, please contact Rosen Law Firm at (866) 767-3653 or [email protected].
The outcome of this lawsuit could have far-reaching implications for the biotech industry and the regulatory approval process for new drugs. Stay tuned for updates on this developing story.
